Largest PSA bounce study eases worry of prostate cancer returning
Prostate cancer patients who have a temporary rise in their prostate specific antigen (PSA) levels after radiation therapy - called a PSA bounce - are not at an increased risk of their cancer coming back any more than those who don't have a temporary rise, according to the largest study of its kind presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
External beam radiation therapy and radiation seed implants are two of the main treatments for prostate cancer. Since these treatments are minimally invasive, have short recovery periods and often help men preserve their sexual and urinary function, many men with prostate cancer prefer radiation over other treatments, including surgery. The PSA bounce is common in half of all men who have radiation treatment for prostate cancer. Increased levels of PSA, which is a protein produced by the prostate, may be a sign of prostate cancer.
"I believe the results of our study should help reduce the stress and uncertainty for men who experience a PSA bounce after radiation knowing that this doesn't represent a recurrence or put them at increased risk for cancer coming back later on," said Eric Horwitz, M.D., lead author of the study and clinical director of the radiation oncology department at Fox Chase Cancer Center in Philadelphia. "This study significantly impacts the clinical practice for both radiation oncologists and urologists. Clinicians should consider additional PSA tests after the initial bounce to see if the PSA levels return to normal before concluding that cancer has recurred and recommending additional treatment."
The study involved more than 7,500 men in 19 institutions who were treated for prostate cancer with either external beam radiation therapy or radiation seed implants. Findings show that over a 10-year period, there was no difference in cancer recurrence between those who had a PSA bounce and those who did not.
For more information on radiation therapy for prostate cancer, visit www.rtanswers.org.
The abstract, "The Post-Treatment PSA Bounce for Prostate Cancer Patients Treated with External Beam RT or Permanent Brachytherapy Alone is not Biochemically or Clinically Significant," will be presented in a scientific session on Wednesday, November 8, at 1:00 p.m. To speak to the lead author of the study, Eric Horwitz, M.D., please call Beth Bukata or Julie Moore November 5-8 in the ASTRO Press Room at the Pennsylvania Convention Center at 215-418-2257 or 215-418-2258. You may also e-mail her at [email protected].
ASTRO is the largest radiation oncology society in the world, with more than 8,500 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.